Oxandrolone hereditary angioedema

The drug was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss, and is used as part of treatment for HIV/AIDS . It had also been shown to be partially successful in treating cases of osteoporosis . However, in part due to bad publicity from its illicit use by bodybuilders , production of Anavar was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, which changed its name to Savient Pharmaceuticals who, following successful clinical trials in 1995, released it under the tradename Oxandrin. BTG subsequently won approvals for orphan drug status by the Food and Drug Administration (FDA) for treating alcoholic hepatitis , Turner syndrome , and HIV-induced weight loss . It is also indicated as an offset to protein catabolism caused by long-term administration of corticosteroids .

Hereditary angioedema (HAE or inherited C1 inhibitor [C1INH] deficiency) is a rare genetic disorder resulting from deficiency (type I) or dysfunction (type II) of C1INH. It is characterized by recurrent episodes of angioedema without pruritus or urticaria, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although swelling resolves spontaneously in two to five days in the absence of treatment, angioedema is often temporarily debilitating, and laryngeal angioedema may cause fatal asphyxiation.

Oxandrolone hereditary angioedema

oxandrolone hereditary angioedema

Media:

oxandrolone hereditary angioedemaoxandrolone hereditary angioedemaoxandrolone hereditary angioedemaoxandrolone hereditary angioedemaoxandrolone hereditary angioedema